Puma Biotechnology Q3 Net Income Falls to $6.0M
Q3 2026 revenue was $55.1 million, up from $54.5 million a year earlier; GAAP net income fell to $6.0 million from $8.8 million.
Q3 2026 total revenue was $55.1M, versus $54.5M in Q3 2025. GAAP net income fell to $6.0M from $8.8M.Material DetailsContext by AI AnalystPuma's results show a commercial product business alongside expanding alisertib clinical development, with modestly higher revenue but lower year-over-year earni…